Premium Nahrungsergänzungsmittel | artgerecht

Artesunate Clinical Use: Mechanism, Dosage and Effects

Artesunate is clinically used primarily to treat severe malaria. It is a highly effective drug derived from artemisinin and is considered the first-line therapy by the WHO.

Regular tips about health Regular tips about health

Things worth knowing about "artesunate clinical"

Artesunate is clinically used primarily to treat severe malaria. It is a highly effective drug derived from artemisinin and is considered the first-line therapy by the WHO.

What is Artesunate?

Artesunate is a semi-synthetic derivative of artemisinin, a natural compound extracted from the plant Artemisia annua (sweet wormwood). It belongs to the class of artemisinin-based compounds and is globally recognized as one of the most effective medicines against malaria. The World Health Organization (WHO) recommends intravenous artesunate as the first-line treatment for severe malaria.

Clinical Indications

In clinical practice, artesunate is primarily used in the following situations:

Severe malaria (Plasmodium falciparum): This is the primary indication. Artesunate is administered intravenously or intramuscularly to achieve rapid antiparasitic effects.
Uncomplicated malaria: In combination with other antimalarial agents (artemisinin-based combination therapies, ACT), oral artesunate is used to treat uncomplicated malaria.
Drug-resistant malaria: When other antimalarials fail (e.g., chloroquine-resistant strains), artesunate often remains effective.
Research in other diseases: Preclinical and clinical studies are investigating artesunate for potential use in certain cancers and autoimmune conditions, although it is not yet officially approved for these indications.

Mechanism of Action

Artesunate is rapidly converted in the body to its active metabolite dihydroartemisinin (DHA). The exact mechanism is not yet fully elucidated, but key actions include:

Reactive oxygen species (ROS): The endoperoxide bridge in the artemisinin molecule reacts with heme iron within the parasite, generating toxic free radicals that damage and kill the parasite.
Inhibition of parasite metabolism: Artesunate disrupts protein synthesis and other vital processes of the malaria pathogen.
Rapid reduction of parasite load: Due to its fast onset of action, artesunate significantly reduces the number of parasites in the blood within hours.

Clinical Administration and Dosage

In clinical settings, artesunate is administered differently depending on the severity of the disease:

Intravenous (IV): For severe malaria, artesunate is given as an intravenous infusion. The WHO-recommended dose is 2.4 mg/kg body weight at the start, at 12 and 24 hours, and then once daily thereafter.
Intramuscular (IM): As an alternative to IV administration when venous access is not available.
Oral: Combined with a partner drug (e.g., amodiaquine, lumefantrine) for the treatment of uncomplicated malaria.
Rectal: Rectal suppositories are used primarily in children in areas with limited medical access as a first-step measure before transport to a hospital.

Side Effects and Safety Profile

Artesunate is generally well tolerated, particularly compared to older antimalarials such as quinine. Possible side effects include:

Delayed haemolysis: A delayed haemolytic anaemia may occur several weeks after treatment of severe malaria. This phenomenon is known as Post-Artesunate Delayed Haemolysis (PADH) and requires clinical follow-up.
Neutropenia: A temporary decrease in white blood cells may occur.
Elevated liver enzymes: Occasionally, increased transaminase levels are observed.
Cardiac arrhythmias: Rare, mainly with high doses or prolonged use.
Injection site reactions: Possible with intravenous or intramuscular administration.

Clinical Significance and Guidelines

The WHO has classified artesunate as an essential medicine and recommends it in current malaria treatment guidelines as the primary therapy for severe malaria in both adults and children. Compared to quinine, the former standard of care, artesunate has demonstrated significantly higher efficacy and a more favorable safety profile in clinical trials. Major randomized controlled studies such as AQUAMAT (children in Africa) and SEAQUAMAT (adults in Southeast Asia) have confirmed the superiority of artesunate over quinine in severe malaria.

Special Patient Groups

Children: Artesunate is approved for use in children and shows good efficacy and tolerability.
Pregnant women: In the second and third trimesters, artesunate is recommended for severe malaria. In the first trimester, caution is advised and the clinical benefit must be weighed against potential risks.
Patients with renal impairment: Dose adjustment is generally not required.

References

World Health Organization (WHO) - Guidelines for the Treatment of Malaria, 3rd edition (2015). Available at: https://www.who.int/publications/i/item/9789241549127
Dondorp AM et al. - Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. The Lancet, 2010;376(9753):1647-1657.
Sinclair D et al. - Artesunate versus quinine for treating severe malaria. Cochrane Database of Systematic Reviews, 2012.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.